Lisa Takagi

Japan

Managing Editor, Japan at The Pink Sheet

Managing Editor, Japan at Scrip

Featured in: Favicon

informa.com (+4) Favicon

signalhfx.ca Favicon

itmedia.co.jp Favicon

citeline.com (+1)

Articles

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

3 weeks ago | insights.citeline.com | Lisa Takagi

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants JEC Aims To Help Ventures Without Presence Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market. JEC started by several firms in market expertise in Japan including Bushu Pharma. (Shutterstock)
Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

3 weeks ago | insights.citeline.com | Lisa Takagi |Joseph Haas |Anju Ghangurde |Vibha Ravi

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding PlatformPlus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

4 weeks ago | insights.citeline.com | Lisa Takagi

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market $1.4m Funding Per StartupJapanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
US-China Tariff War Pressures Pharma’s Complex Supply Chain

1 month ago | insights.citeline.com | Lisa Takagi

US-China Tariff War Pressures Pharma’s Complex Supply ChainExecs Air On-The-Ground Concerns At Japan EventAlthough pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.
AstraZeneca Logs Japan Growth Despite Price Cuts

1 month ago | insights.citeline.com | Lisa Takagi

AstraZeneca Logs Japan Growth Despite Price CutsStrong Pipeline In Its Third-Largest Market AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.
Japan Looks To Build Domestic Capacity In New Modalities

1 month ago | insights.citeline.com | Lisa Takagi

Japan Looks To Build Domestic Capacity In New ModalitiesNew Govt Funding For CGT Production Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem. Japan's METI has budgeted JPY38.3bn to support building domestic CDMOs for cell and gene therapy. (Shutterstock)
Japan Identifies Drugs ‘In Urgent Need’ Of Development

1 month ago | insights.citeline.com | Lisa Takagi

Japan Identifies Drugs ‘In Urgent Need’ Of Development14 Products On ‘A List’ Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development. Japan shifts towards more active in addressing drug gap through its policies. (Shutterstock)
Japan Pushes Generic Industry Reforms Via New Govt Fund

1 month ago | insights.citeline.com | Lisa Takagi

Japan Pushes Generic Industry Reforms Via New Govt FundEnd To ‘Small Volume, High Mix’ EyedAmid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera Biosimilars

1 month ago | insights.citeline.com | Joseph Haas |Lisa Takagi

Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera BiosimilarsPlus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

1 month ago | insights.citeline.com | Lisa Takagi

Japan T-Reg Venture RegCell Raises New Funds, Relocates To USLead Therapy Into Clinic This Year Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding. A Japanese cell therapy venture RegCell relocated its HQ from Japan to US with $48.5m financing. (Shutterstock)